Centessa Pharmaceuticals plc (CNTA) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Mario Alberto Accardi	Chief Executive Officer & Director	1.23M	1986
Gregory Weinhoff	Chief Business Officer	655,004	1971
Iqbal J. Hussain	Chief Legal Officer, Chief Compliance Officer & Company Secretary	768,575	1981
Stephen J. Kanes	Head of R&D and Chief Medical Officer	823,800	1965
John J. Crowley	Chief Financial Officer	853,860	1974
Charlene Stoudt	Senior Vice President of Clinical Development Operations	0	N/A
Raphael Deferiere	Senior VP & Chief Accounting Officer	0	1980
Karen Anderson	Chief People Officer	0	1968
Kristen K. Sheppard	Senior Vice President of Investor Relations & Corporate Communications	0	N/A
Tia L. Bush	Chief Technology & Quality Officer	0	1971
Kimberly A. McCormick	Senior Vice President of Regulatory Affairs & Medical Writing	0	N/A

Name

Title

Pay

Year Born

Mario Alberto Accardi

Chief Executive Officer & Director

1.23M

1986

Gregory Weinhoff

Chief Business Officer

655,004

1971

Iqbal J. Hussain

Chief Legal Officer, Chief Compliance Officer & Company Secretary

768,575

1981

Stephen J. Kanes

Head of R&D and Chief Medical Officer

823,800

1965

John J. Crowley

Chief Financial Officer

853,860

1974

Charlene Stoudt

Senior Vice President of Clinical Development Operations

N/A

Raphael Deferiere

Senior VP & Chief Accounting Officer

1980

Karen Anderson

Chief People Officer

1968

Kristen K. Sheppard

Senior Vice President of Investor Relations & Corporate Communications

N/A

Tia L. Bush

Chief Technology & Quality Officer

1971

Kimberly A. McCormick

Senior Vice President of Regulatory Affairs & Medical Writing

N/A

Description

Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.